Chimeric antigen receptor (CAR) T-cell therapy has led to significant success in hematological malignancies especially in R/R B-ALL where autologous CD19 CAR T-cells have shown remarkable anti-leukemia effects and CR rates of 70 to 90% (57). This evidence concerns the gene CD19 and leukemia.